June 1st 2025
"These long-term results continue to support [pembrolizumab's] use as a standard of care for patients at increased risk of recurrence," says Naomi B. Haas, MD.
Camillo Porta, MD, offers key takeaways from CheckMate 9ER trial in renal cell carcinoma
February 26th 2025"At ASCO GU, we presented the final analysis of the study, which confirmed the superiority of a combination over the TKI monotherapy in terms of both progression-free survival as well as overall survival," says Camillo Porta, MD.
Final CheckMate 9ER data show long-term efficacy of nivolumab/cabozantinib in RCC
February 20th 2025Robert J. Motzer, MD, reported that median PFS was 16.4 months in the nivolumab plus cabozantinib arm (95% CI, 12.5-19.3) vs 8.3 months in the sunitinib arm (95% CI, 7.0-9.7) (HR=0.58, 95% CI, 0.49-0.70).